Ticker Launch
Sign inTry it free

IPO · AVLN

Avalyn Pharma Inc.

Formerly Genoa Pharmaceuticals, Inc.

Avalyn Pharma Inc. (AVLN) priced its initial public offering on Apr 30, 2026 at $18.00 per share, raising $300M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $752.6M. Morgan Stanley was lead-left underwriter, joined by Jefferies, Evercore ISI and Guggenheim. Goodwin Procter advised the company and Davis Polk advised the underwriters.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled formulations of approved oral medicines to treat serious, rare respiratory diseases, with a current pipeline focused on pulmonary fibrosis.

Status
IPO
Ticker
AVLN
Exchange
Nasdaq Global Select
Priced
Apr 30, 2026
IPO price
$18.00
Raised
$300M
Market cap at IPO price
$752.6M
First filed
Apr 8, 2026
Underwriters
Morgan Stanley, Jefferies, Evercore ISI and Guggenheim
Company counsel
Goodwin Procter
Underwriters' counsel
Davis Polk
Sector
Biotech & pharma
Country / state
MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2026